Three-year results from the ALASCCA trial (NCT02647099), presented at the 2025 ASCO Gastrointestinal Cancer Symposium, showed ...

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance ...

Daily low-dose aspirin reduced the risk for colorectal cancer recurrence by roughly half in patients with mutations in the ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) ...

In a nutshell Researchers discovered how a specific genetic mutation (PIK3CA) changes the way blood vessel cancers grow and ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.